Fact Sheet: President Donald J. Trump Ensures American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve

Summary:An executive order directs the federal government to fill the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) with critical drug components to strengthen U.S. pharmaceutical supply chain resilience and reduce dependence on foreign sources.Key actions in the executive order:Identify critical drugs: ASPR to develop a list of approximately twenty-six drugs vital to national health and security and prepare SAPIR to store their active pharmaceutical ingredients.Six-month API stockpile: ASPR to obtain a six-month supply of critical APIs, prioritizing domestic manufacturers when possible, and place them in SAPIR.Expand coverage: Update the twenty twenty-two list of eighty-six essential medicines and propose plans to secure a six-month API supply for these as well.Redundancy: Develop a proposal to open a second SAPIR repository to enhance resiliency.Rationale and context:Current vulnerability: Only about ten percent of APIs for U.S. prescription drugs are produced domestically, creating risks from foreign supply disruptions.Strategic stockpiling: APIs are relatively lower-cost with longer shelf lives, making them suitable for reserves that can buffer emergencies and shocks.Policy continuity: Builds on earlier actions from twenty twenty and May twenty twenty-five to onshore medical supply chains, ease regulatory barriers, and pursue drug price reforms.Prior related actions cited:Twenty twenty executive order to increase domestic procurement of essential medicines, medical countermeasures, and critical inputs, and assess vulnerabilities.Creation of SAPIR in twenty twenty to stockpile APIs.May twenty twenty-five executive orders to remove regulatory barriers for domestic drug manufacturing and implement most-favored-nation drug pricing; letters to seventeen pharmaceutical companies encouraging competitive pricing and domestic production.